• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tammenoms Bakker Juliet bought $305,456 worth of shares (5,000 units at $61.09), increasing direct ownership by 17% to 34,840 units (SEC Form 4)

    5/21/24 4:11:17 PM ET
    $RXST
    Ophthalmic Goods
    Health Care
    Get the next $RXST alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Tammenoms Bakker Juliet

    (Last) (First) (Middle)
    C/O RXSIGHT, INC.
    100 COLUMBIA

    (Street)
    ALISO VIEJO CA 92656

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    RxSight, Inc. [ RXST ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/17/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/17/2024 P 5,000 A $61.0913 34,840 D
    Common Stock 1,548 I See footnote(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. These securities are held by a trust. The Reporting Person, a member of the Issuer's board of directors, is the Investment Trustee of such trust and may be deemed to share voting, investment and dispositive power with respect to such securities. The Reporting Person disclaims beneficial ownership over such securities except to the extent of her pecuniary interest therein, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
    /s/ Cristiana Blauth Oliveira as Attorney-in-fact for Juliet Tammenoms Bakker 05/21/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RXST alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RXST

    DatePrice TargetRatingAnalyst
    7/15/2025$9.00Overweight → Equal-Weight
    Morgan Stanley
    7/10/2025$9.00Buy → Hold
    Jefferies
    7/9/2025Outperform → Perform
    Oppenheimer
    7/9/2025$9.00Overweight → Equal Weight
    Wells Fargo
    7/9/2025Buy → Neutral
    BTIG Research
    5/19/2025$25.00Equal Weight → Overweight
    Wells Fargo
    4/15/2025$18.00Neutral
    Piper Sandler
    4/9/2025$16.00Buy → Neutral
    UBS
    More analyst ratings

    $RXST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Corley Jesse Anderson bought $100,004 worth of shares (3,210 units at $31.15) (SEC Form 4)

    4 - RxSight, Inc. (0001111485) (Issuer)

    1/17/25 7:08:42 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    Director Corley Jesse Anderson bought $1,014,570 worth of shares (22,476 units at $45.14), increasing direct ownership by 18% to 38,438 units (SEC Form 4)

    4 - RxSight, Inc. (0001111485) (Issuer)

    11/14/24 7:14:14 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    Tammenoms Bakker Juliet bought $305,456 worth of shares (5,000 units at $61.09), increasing direct ownership by 17% to 34,840 units (SEC Form 4)

    4 - RxSight, Inc. (0001111485) (Issuer)

    5/21/24 4:11:17 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $RXST
    SEC Filings

    View All

    Amendment: RxSight Inc. filed SEC Form 8-K: Leadership Update

    8-K/A - RxSight, Inc. (0001111485) (Filer)

    8/15/25 4:30:26 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by RxSight Inc.

    SCHEDULE 13G/A - RxSight, Inc. (0001111485) (Subject)

    8/13/25 10:24:20 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    SEC Form 10-Q filed by RxSight Inc.

    10-Q - RxSight, Inc. (0001111485) (Filer)

    8/7/25 4:23:01 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $RXST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cohen Raymond W was granted 35,668 shares (SEC Form 4)

    4 - RxSight, Inc. (0001111485) (Issuer)

    8/4/25 4:47:56 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    SEC Form 3 filed by new insider Cohen Raymond W

    3 - RxSight, Inc. (0001111485) (Issuer)

    8/4/25 4:46:22 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    Director Link William J Phd was granted 10,752 shares, increasing direct ownership by 40% to 37,855 units (SEC Form 4)

    4 - RxSight, Inc. (0001111485) (Issuer)

    6/4/25 9:38:26 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $RXST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RxSight, Inc. to Present at the Wells Fargo Healthcare Conference

    ALISO VIEJO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Wells Fargo Healthcare Conference in Boston. RxSight's management is scheduled to present on Thursday, September 4, 2025, at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time. A live and archived webcast of the presentation will be available at: https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract

    8/14/25 4:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight, Inc. Reports Second Quarter 2025 Financial Results

    ALISO VIEJO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2025. Key Company Highlights Reported second quarter 2025 revenue of $33.6 million, representing a decrease of 4% compared to the second quarter of 2024, reflecting: The sale of 27,380 Light Adjustable Lenses (LAL®/LAL+®), representing a 13% increase in procedure volume compared to the second quarter of 2024;The sale of 40 Light Delivery Devices (LDD™s), representing a 49% decrease compared to the sec

    8/7/25 4:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors

    ALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the appointment of Raymond W. Cohen to its Board of Directors. "We are thrilled to welcome Raymond W. Cohen to the RxSight Board of Directors," said J. Andy Corley, Chairman of the Board at RxSight. "Ray's extensive track record in leading and scaling medical technology companies will be invaluable as we advance our strategy and enter the next phase of growth. His insights and guidance will help us expand the reach of the RxSight® Light Adjustable Lens system,

    8/4/25 8:05:00 AM ET
    $AXNX
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care
    Ophthalmic Goods

    $RXST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RxSight downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded RxSight from Overweight to Equal-Weight and set a new price target of $9.00

    7/15/25 8:39:07 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight downgraded by Jefferies with a new price target

    Jefferies downgraded RxSight from Buy to Hold and set a new price target of $9.00

    7/10/25 8:36:38 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight downgraded by Oppenheimer

    Oppenheimer downgraded RxSight from Outperform to Perform

    7/9/25 8:19:00 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $RXST
    Financials

    Live finance-specific insights

    View All

    RxSight, Inc. Reports Second Quarter 2025 Financial Results

    ALISO VIEJO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2025. Key Company Highlights Reported second quarter 2025 revenue of $33.6 million, representing a decrease of 4% compared to the second quarter of 2024, reflecting: The sale of 27,380 Light Adjustable Lenses (LAL®/LAL+®), representing a 13% increase in procedure volume compared to the second quarter of 2024;The sale of 40 Light Delivery Devices (LDD™s), representing a 49% decrease compared to the sec

    8/7/25 4:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025

    ALISO VIEJO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 633359. The call will also be broadcast live in listen-only mode via a link on the company's investor relations we

    7/24/25 4:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance

    ALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary financial results for the second quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Tuesday, July 8, 2025, at 5:00 p.m. Eastern Time. Preliminary Second Quarter 2025 Results Preliminary second quarter 2025 revenue is expected to be approximately $33.6 million, representing a decrease of 4% compared to the prior year period, and a decrease of 11% compared to the first quarter of 2025, driven by: The

    7/8/25 4:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $RXST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RxSight Inc.

    SC 13G/A - RxSight, Inc. (0001111485) (Subject)

    11/14/24 5:46:12 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by RxSight Inc.

    SC 13G/A - RxSight, Inc. (0001111485) (Subject)

    11/12/24 4:50:57 PM ET
    $RXST
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by RxSight Inc.

    SC 13G/A - RxSight, Inc. (0001111485) (Subject)

    11/12/24 9:40:27 AM ET
    $RXST
    Ophthalmic Goods
    Health Care

    $RXST
    Leadership Updates

    Live Leadership Updates

    View All

    Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

    Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

    5/30/24 4:00:00 AM ET
    $ALC
    $NARI
    $OCS
    Ophthalmic Goods
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    RxSight, Inc. Appoints Dr. Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors

    ALISO VIEJO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced the appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors. "We are very excited to continue to strengthen the RxSight Board of Directors with the additions of Dr. Fountain and Ms. Maniar. Their diverse healthcare leadership experience will support the strategic advancement of the company through its next chapter of growth," said J. Andy Corley, Chair of the Board of Directors. "We look forward to their respective contributions as the RxSight® Lig

    1/4/22 4:05:00 PM ET
    $RXST
    Ophthalmic Goods
    Health Care